2021
Distinct Roles of Type I and Type III Interferons during a Native Murine β Coronavirus Lung Infection
Sharma L, Peng X, Qing H, Hilliard BK, Kim J, Swaminathan A, Tian J, Israni-Winger K, Zhang C, Habet V, Wang L, Gupta G, Tian X, Ma Y, Shin HJ, Kim SH, Kang MJ, Ishibe S, Young LH, Kotenko S, Compton S, Wilen CB, Wang A, Dela Cruz CS. Distinct Roles of Type I and Type III Interferons during a Native Murine β Coronavirus Lung Infection. Journal Of Virology 2021, 96: e01241-21. PMID: 34705554, PMCID: PMC8791255, DOI: 10.1128/jvi.01241-21.Peer-Reviewed Original ResearchConceptsType I interferonType III interferonsI interferonIII interferonsCoronavirus infectionInterferon deficiencyViral clearanceViral loadLung infectionType IHealthy young patientsImproved host survivalHost survivalRole of interferonMurine coronavirus infectionMajor health care threatViral burdenYounger patientsEarly diseaseIntranasal routeInterferon treatmentSublethal infectionEarly treatmentLethal infectionTissue injuryJAK-inhibitor and type I interferon ability to produce favorable clinical outcomes in COVID-19 patients: a systematic review and meta-analysis
Walz L, Cohen AJ, Rebaza AP, Vanchieri J, Slade MD, Dela Cruz CS, Sharma L. JAK-inhibitor and type I interferon ability to produce favorable clinical outcomes in COVID-19 patients: a systematic review and meta-analysis. BMC Infectious Diseases 2021, 21: 47. PMID: 33430799, PMCID: PMC7797881, DOI: 10.1186/s12879-020-05730-z.Peer-Reviewed Original ResearchConceptsCOVID-19 patientsType I interferonOdds of mortalityPositive clinical outcomesClinical outcomesI interferonICU admissionExcessive cytokine releaseType I interferon treatmentStandard treatment groupOdds of dischargeFavorable clinical outcomeNon-randomized trialsJanus kinase inhibitorSearch of MEDLINETerms of mortalityKinase inhibitor treatmentHospital dischargeCytokine releaseInterferon treatmentPotential antiviral candidatesNovel therapiesTreatment outcomesTreatment groupsAntiviral candidates
1988
LYTIC ANTI-ENDOTHELIAL CELL ANTIBODIES IN HAEMOLYTIC-URAEMIC SYNDROME
Leung D, Havens P, Moake J, Kim M, Pober J. LYTIC ANTI-ENDOTHELIAL CELL ANTIBODIES IN HAEMOLYTIC-URAEMIC SYNDROME. The Lancet 1988, 332: 183-186. PMID: 2899661, DOI: 10.1016/s0140-6736(88)92287-8.Peer-Reviewed Original ResearchConceptsAnti-endothelial cell antibodiesHaemolytic uraemic syndromeThrombotic thrombocytopenic purpuraCell antibodiesComplement-fixing IgGDisorder of immunoregulationAnti-endothelial antibodiesEndothelial cell antigensCultured human umbilical vein endothelial cellsGamma-interferon treatmentHuman umbilical vein endothelial cellsUmbilical vein endothelial cellsAdult patientsVein endothelial cellsThrombocytopenic purpuraIgM antibodiesVascular injuryInterferon treatmentUraemic syndromeGamma interferonCell antigensControl seraEndothelial cellsAntibodiesSerum
1984
Urinary excretion of interferon, albumin, and beta 2-microglobulin during interferon treatment.
Sumpio BE, Ernstoff MS, Kirkwood JM. Urinary excretion of interferon, albumin, and beta 2-microglobulin during interferon treatment. Cancer Research 1984, 44: 3599-603. PMID: 6378373.Peer-Reviewed Original ResearchConceptsInterferon therapyUrinary excretionInterferon activityPhase I trialSerum interferon activityUrinary betaInterferon administrationI trialSignificant nephrotoxicityTubular lesionsUrinary levelsInterferon treatmentHighest dosing levelDosing levelsTherapyInterferonExcretionTreatmentLow affinityAlbuminBetaNephrotoxicityPatientsLesionsPharmacokinetics
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply